LLY News and Press, Eli Lilly and Company From 06/24/24

2024-06-24 09:21:19 ET More on Altimmune Altimmune: Going All-In On Pemvidutide Altimmune: A Potential Minor Player In The Massive GLP-1 Space Altimmune's Pemvidutide Is Not To Be Dismissed Altimmune Q1 2024 Earnings Preview Altimmune falls after Q4 r...

2024-06-24 09:00:07 ET Akash Tewari from Jefferies issued a price target of $1,015.00 for LLY on 2024-06-24 07:53:00. The adjusted price target was set to $1,015.00. At the time of the announcement, LLY was trading at $883.88. The overall price target consensus is at $60...

2024-06-24 04:53:13 ET Summary Follow along as we discuss a potential top formation in Lilly's stock price and the importance of proper evidence before taking a short position. We share our methodology that shows at what price level to turn more cautious if you are long Lilly shar...

2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...

2024-06-22 19:33:06 ET The AI driven massive surge in Nvidia Corp has pushed it market cap well above the $3.0 trillion mark. Meanwhile, these three stocks look ripe to hit their first trillion in valuation. Let’s dive deeper and see what each of these have in store for inves...

2024-06-22 11:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly And Alzheimer's Disease: The Paucity Of Progress ResMed, Philips under pressur...

2024-06-22 08:27:42 ET More on Eli Lilly, Philips, etc. Eli Lilly: The Party Is Probably Nearing The End Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Lilly weight loss drug tirzepatide meets p...

2024-06-21 16:33:06 ET More on Takeda Pharmaceutical Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript Takeda Pharmaceutical Company Limited 2023...

2024-06-21 16:24:19 ET More on Eli Lilly Eli Lilly: The Party Is Probably Nearing The End Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Hims & Hers defended at BofA as Lilly fights compound...

Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution PR Newswire In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events ...